Literature DB >> 15309680

Association between the PPARalpha-L162V polymorphism and components of the metabolic syndrome.

Julie Robitaille1,2, Charles Brouillette1,3, Alain Houde1, Simone Lemieux2, Louis Pérusse3, André Tchernof1,2,4, Daniel Gaudet5, Marie-Claude Vohl6,7.   

Abstract

Genetic factors, alone or in interaction with components of the diet, are thought to be involved in the development of the metabolic syndrome. The objective of our study was first to compare the frequency of the peroxisome proliferator-activated receptor (PPAR)alpha-L162V polymorphism in a sample of men with and without the metabolic syndrome as defined by the National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATPIII) guidelines, and secondly, to evaluate gene-diet interaction effects on features of the metabolic syndrome. The PPARalpha-L162V genotype was determined in a sample of 632 men by a polymerase chain reaction-restriction length polymorphism (PCR-RFLP)-based method; fat as well as saturated fat intakes were evaluated by a dietitian-administered food frequency questionnaire. The frequency of the V162 allele was similar in men with ( n=281) and without ( n=351) the metabolic syndrome ( chi(2)=0.03, p=0.84) but was higher in subjects having simultaneously abdominal obesity, hypertriglyceridemia, and low high-density lipoprotein cholesterol (HDL-C) levels ( chi(2)=3.73, p=0.05). Carriers of the V162 were characterized by higher plasma apolipoprotein B and triglyceride (TG) levels ( p=0.10, p=0.004). In a model including the PPARalpha-L162V polymorphism, fat or saturated fat, its interaction, and covariates (smoking habits, and energy and alcohol intake), the interaction explained a significant percentage of the variance observed in waist circumference ( p<0.05). In conclusion, the PPARalpha-L162V polymorphism alone or in interaction with dietary fat intake is associated with components of the metabolic syndrome.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15309680     DOI: 10.1007/s10038-004-0177-9

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  36 in total

1.  Differential effects of PPARalpha activators on induction of ectopic expression of tissue-specific fatty acid binding protein genes in the mouse liver.

Authors:  K Motojima
Journal:  Int J Biochem Cell Biol       Date:  2000-10       Impact factor: 5.085

2.  Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management.

Authors:  Scott M Grundy; Barbara Hansen; Sidney C Smith; James I Cleeman; Richard A Kahn
Journal:  Circulation       Date:  2004-02-03       Impact factor: 29.690

Review 3.  The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation.

Authors:  K Schoonjans; B Staels; J Auwerx
Journal:  Biochim Biophys Acta       Date:  1996-07-26

4.  Control of human muscle-type carnitine palmitoyltransferase I gene transcription by peroxisome proliferator-activated receptor.

Authors:  C Mascaró; E Acosta; J A Ortiz; P F Marrero; F G Hegardt; D Haro
Journal:  J Biol Chem       Date:  1998-04-10       Impact factor: 5.157

5.  Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay.

Authors:  G Krey; O Braissant; F L'Horset; E Kalkhoven; M Perroud; M G Parker; W Wahli
Journal:  Mol Endocrinol       Date:  1997-06

6.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

7.  Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey.

Authors:  Earl S Ford; Wayne H Giles; William H Dietz
Journal:  JAMA       Date:  2002-01-16       Impact factor: 56.272

8.  The human peroxisome proliferator-activated receptor alpha gene: identification and functional characterization of two natural allelic variants.

Authors:  A Sapone; J M Peters; S Sakai; S Tomita; S S Papiha; R Dai; F K Friedman; F J Gonzalez
Journal:  Pharmacogenetics       Date:  2000-06

9.  Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis.

Authors:  P Costet; C Legendre; J Moré; A Edgar; P Galtier; T Pineau
Journal:  J Biol Chem       Date:  1998-11-06       Impact factor: 5.157

10.  The peroxisome proliferator-activated receptor alpha L162V mutation is associated with reduced adiposity.

Authors:  Yohan Bossé; Jean-Pierre Després; Claude Bouchard; Louis Pérusse; Marie-Claude Vohl
Journal:  Obes Res       Date:  2003-07
View more
  27 in total

Review 1.  Host nucleotide polymorphism in hepatitis B virus-associated hepatocellular carcinoma.

Authors:  Shilu Mathew; Hany Abdel-Hafiz; Abbas Raza; Kaneez Fatima; Ishtiaq Qadri
Journal:  World J Hepatol       Date:  2016-04-08

2.  Perfluorooctanoic acid activates multiple nuclear receptor pathways and skews expression of genes regulating cholesterol homeostasis in liver of humanized PPARα mice fed an American diet.

Authors:  J J Schlezinger; H Puckett; J Oliver; G Nielsen; W Heiger-Bernays; T F Webster
Journal:  Toxicol Appl Pharmacol       Date:  2020-08-19       Impact factor: 4.219

3.  Association between PPARs Gene Functional Polymorphisms and Ischemic Stroke in Chinese Uyghur Population.

Authors:  Y Tong; L Cai; Z Wang; Y Zhang; X Guan; F Zhan; J Liu; Q Lu
Journal:  J Nutr Health Aging       Date:  2019       Impact factor: 4.075

Review 4.  PPAR-α as a key nutritional and environmental sensor for metabolic adaptation.

Authors:  Alejandra V Contreras; Nimbe Torres; Armando R Tovar
Journal:  Adv Nutr       Date:  2013-07-01       Impact factor: 8.701

Review 5.  Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand?

Authors:  Jeffrey M Peters; Connie Cheung; Frank J Gonzalez
Journal:  J Mol Med (Berl)       Date:  2005-06-23       Impact factor: 4.599

Review 6.  Prevention of overweight and obesity: how effective is the current public health approach.

Authors:  Ruth S M Chan; Jean Woo
Journal:  Int J Environ Res Public Health       Date:  2010-02-26       Impact factor: 3.390

Review 7.  PPARalpha: energy combustion, hypolipidemia, inflammation and cancer.

Authors:  Sean R Pyper; Navin Viswakarma; Songtao Yu; Janardan K Reddy
Journal:  Nucl Recept Signal       Date:  2010-04-16

Review 8.  Genetics of metabolic syndrome.

Authors:  Tisha Joy; Piya Lahiry; Rebecca L Pollex; Robert A Hegele
Journal:  Curr Diab Rep       Date:  2008-04       Impact factor: 4.810

9.  Peroxisome proliferator-activated receptor [alpha] genetic variation interacts with n-6 and long-chain n-3 fatty acid intake to affect total cholesterol and LDL-cholesterol concentrations in the Atherosclerosis Risk in Communities Study.

Authors:  Kelly A Volcik; Jennifer A Nettleton; Christie M Ballantyne; Eric Boerwinkle
Journal:  Am J Clin Nutr       Date:  2008-06       Impact factor: 7.045

10.  Periostin promotes liver steatosis and hypertriglyceridemia through downregulation of PPARα.

Authors:  Yan Lu; Xing Liu; Yang Jiao; Xuelian Xiong; E Wang; Xiaolin Wang; Zhijian Zhang; Huijie Zhang; Lingling Pan; Youfei Guan; Dongsheng Cai; Guang Ning; Xiaoying Li
Journal:  J Clin Invest       Date:  2014-07-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.